A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women

Trial Profile

A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Blosozumab (Primary) ; Blosozumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Biomarker
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Dec 2012 New source identified and integrated: ClinicalTrials.gov record.
    • 28 Oct 2012 New trial record
    • 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top